Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 6.8% – What’s Next?

Tiziana Life Sciences Ltd (NASDAQ:TLSA)’s stock price rose 6.8% on Wednesday . The stock traded as high as $1.3060 and last traded at $1.25. Approximately 120,896 shares changed hands during trading, a decline of 18% from the average daily volume of 147,315 shares. The stock had previously closed at $1.17.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tiziana Life Sciences in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Tiziana Life Sciences Stock Performance

The stock has a fifty day moving average of $1.38 and a 200-day moving average of $1.63.

Hedge Funds Weigh In On Tiziana Life Sciences

Hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC bought a new stake in shares of Tiziana Life Sciences in the first quarter worth $25,000. Rachor Investment Advisory Services LLC acquired a new stake in Tiziana Life Sciences in the 4th quarter valued at $25,000. Bison Wealth LLC bought a new stake in Tiziana Life Sciences during the 4th quarter worth about $30,000. HRT Financial LP bought a new stake in Tiziana Life Sciences during the 4th quarter worth about $36,000. Finally, Marshall Wace LLP acquired a new position in shares of Tiziana Life Sciences during the 2nd quarter worth about $39,000.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.